Trypanosoma brucei PRMT7 (TbPRMT7) is a protein arginine methyltransferase (PRMT) that strictly monomethylates various substrates, thus classifying it as a type III PRMT. However, the molecular basis of its unique product specificity has remained elusive. Here, we present the structure of TbPRMT7 in complex with its cofactor product S-adenosyl-L-homocysteine (AdoHcy) at 2.8 Å resolution and identify a glutamate residue critical for its monomethylation behavior. TbPRMT7 comprises the conserved methyltransferase and β-barrel domains, an N-terminal extension, and a dimerization arm. The active site at the interface of the N-terminal extension, methyltransferase, and β-barrel domains is stabilized by the dimerization arm of the neighboring protomer, providing a structural basis for dimerization as a prerequisite for catalytic activity. Mutagenesis of active-site residues highlights the importance of Glu181, the second of the two invariant glutamate residues of the double E loop that coordinate the target arginine in substrate peptides/proteins and that increase its nucleophilicity. Strikingly, mutation of Glu181 to aspartate converts TbPRMT7 into a type I PRMT, producing asymmetric dimethylarginine (ADMA). Isothermal titration calorimetry (ITC) using a histone H4 peptide showed that the Glu181Asp mutant has markedly increased affinity for monomethylated peptide with respect to the WT, suggesting that the enlarged active site can favorably accommodate monomethylated peptide and provide sufficient space for ADMA formation. In conclusion, these findings yield valuable insights into the product specificity and the catalytic mechanism of protein arginine methyltransferases and have important implications for the rational (re)design of PRMTs.
Trypanosoma brucei PRMT7 (TbPRMT7) is a protein arginine methyltransferase (PRMT) that strictly monomethylates various substrates, thus classifying it as a type III PRMT. However, the molecular basis of its unique product specificity has remained elusive. Here, we present the structure of TbPRMT7 in complex with its cofactor product S-adenosyl-L-homocysteine (AdoHcy) at 2.8 Å resolution and identify a glutamate residue critical for its monomethylation behavior. TbPRMT7 comprises the conserved methyltransferase and β-barrel domains, an N-terminal extension, and a dimerization arm. The active site at the interface of the N-terminal extension, methyltransferase, and β-barrel domains is stabilized by the dimerization arm of the neighboring protomer, providing a structural basis for dimerization as a prerequisite for catalytic activity. Mutagenesis of active-site residues highlights the importance of Glu181, the second of the two invariant glutamate residues of the double E loop that coordinate the target arginine in substrate peptides/proteins and that increase its nucleophilicity. Strikingly, mutation of Glu181 to aspartate converts TbPRMT7 into a type I PRMT, producing asymmetric dimethylarginine (ADMA). Isothermal titration calorimetry (ITC) using a histone H4 peptide showed that the Glu181Asp mutant has markedly increased affinity for monomethylated peptide with respect to the WT, suggesting that the enlarged active site can favorably accommodate monomethylated peptide and provide sufficient space for ADMA formation. In conclusion, these findings yield valuable insights into the product specificity and the catalytic mechanism of protein arginine methyltransferases and have important implications for the rational (re)design of PRMTs.
crystal structure | enzyme catalysis | PRMT | histone methylation | epigenetics P osttranslational modifications of proteins can affect their structure, catalytic activity, and molecular interactions (1) . Methylation of the guanidino group of arginine residues represents a prominent subset of these reactions (2) . Histone arginine methylation is associated with gene silencing and activation (3) ; the modification of arginine residues in a variety of nonhistone proteins, including splicing and transcription factors, can regulate their activity (4, 5) .
Most of the enzymes that catalyze arginine methylation are designated protein arginine methyltransferases (PRMTs) and require the cofactor S-adenosyl-L-methionine (AdoMet) as the methyl donor (6) . Four types of arginine methylation products have been described: ω-N G -monomethylarginine (MMA), asymmetric ω-N G -N G -dimethylarginine (ADMA), symmetric ω-N G -N G' dimethylarginine (SDMA), and δ-N G -monomethylarginine (6, 7) . Accordingly, PRMTs can be categorized into four groups: Type I PRMTs catalyze ADMA formation, type II PRMTs catalyze SDMA formation, type III PRMTs catalyze MMA formation, and type IV PRMTs catalyze δ-N G -monomethylarginine formation. Type I, II, and III PRMTs are widely distributed in nature whereas type IV PRMTs seem to be limited to yeasts and plants (8) . Interestingly, whereas type I and II enzymes catalyze MMA production in addition to their dimethyl products, type III enzymes are the only PRMTs that produce MMA alone. To date, only one methyltransferase, PRMT7, has been reported to have type III activity in mice, humans, and trypanosomes (9) (10) (11) (12) (13) . The function of PRMT7 has been linked to cancer metastasis (4, 14, 15) , DNA damage (16) , pluripotency (17) , and parasite infection (18) .
All PRMTs that have been structurally characterized to date share a conserved catalytic core of about 300-350 residues constituting an AdoMet-binding methyltransferase and a β-barrel domain. Another common feature of PRMTs is the dimerization of the catalytic core that is realized in most cases by noncovalent association of two protomers. Covalent linkage of two PRMT modules has also been observed (19) (20) (21) (22) . Although representative structures of type I, II, and III enzymes have been determined (13, 19, 20, (23) (24) (25) , our understanding of product specificity in these enzymes remains fragmentary. To unravel the molecular basis of the strict MMA activity of PRMT7 enzymes, we determined the X-ray crystal structure of Trypanosoma brucei PRMT7 (TbPRMT7), which was recently reported in two different crystal forms (13) . Although this former study established its dimeric state in solution (13) , we generated a dimerization-deficient mutant where active-site residues remain intact and demonstrated that dimerization is necessary for catalysis. Importantly, we performed extensive mutational analysis and identified and proved for the first time, to our knowledge, that Glu181 is a key residue for monomethylation by TbPRMT7. We carried out isothermal titration calorimetry (ITC) to characterize peptide binding to WT and mutant proteins and assayed product formation. Collectively, these studies provide new insights into the catalytic mechanism and product specificity of this class of enzymes.
Significance
Posttranslational modifications in proteins profoundly modulate their function, and enzymes that generate these modifications therefore have key regulatory roles in a wide array of biological processes. Protein arginine methyltransferases (PRMTs) attach methyl group(s) to arginines and differ in their product specificity, as they form either monomethyl arginine (MMA), asymmetric dimethylarginine (ADMA), or symmetric dimethylarginine (SDMA), each of which relays specific biological signals. Although the members of the PRMT family are structurally highly homologous, the precise molecular basis of their product specificity has not been determined. Based on our structure of TbPRMT7, which explicitly forms MMA, we identified a glutamate residue as a key determinant of its product specificity, and we were able to engineer a TbPRMT7 mutant capable of ADMA formation.
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Results
TbPRMT7 Is a Type III PRMT That Forms only Monomethylarginine.
TbPRMT7 exclusively produces MMA with protein substrates including histones and trypanosomal RNA binding protein 16 (TbRBP16) (12) . TbPRMT7 also effectively methylates a peptide corresponding to the amino acid sequence of the 21 N-terminal residues of human histone H4; however, when the arginine residue at position 3 was replaced by an MMA residue, little or no methylation was observed (13) , suggesting that Arg-3 was the prominent site of methylation in this peptide and that the enzyme was unable to catalyze the addition of a second methyl group on this residue to form SDMA or ADMA. However, the sensitivity of the latter assay was low.
To rule out any possible dimethylation, we used TbRBP16 and human histone H4 peptides (residues 1-21) as substrates in an amino acid analysis method that could detect specific dimethylated substrates on a subfemtomole level. We were able to demonstrate the complete inability of TbPRMT7 to produce dimethylarginine species with TbRBP16 under conditions where 0.01% of such methylated species would be detected ( Fig. 1A) ; sensitivity is based on the ratio of the background radioactivity to the MMA peak radioactivity. We next demonstrated that a histone H4 1-21 peptide acetylated at its N terminus is also an excellent substrate for TbPRMT7 and yields only MMA where 0.02% of a dimethylated product would be detected ( Fig. 1B ). Finally, we were able to directly test for dimethylation using the corresponding peptide that had MMA substituted for arginine at position 3 (H4 1-21 R3MMA); the presence of only monomethylated H4 peptide provides a direct substrate for any dimethylation reaction and limits any competition for methylation between unmethylated and monomethylated species. Again, no production of dimethylated arginine species was detected under conditions where 0.5% would be readily detected (Fig. 1C ). Only a small increase in MMA over the background of automethylation was observed (perhaps due to methylation at arginine-17 and/or arginine- 19) , indicating that the major site of methylation on this peptide is at arginine-3 (Fig. 1C ).
Overall Structure of TbPRMT7. To obtain a detailed picture of the active site at atomic resolution, we set out to determine the X-ray crystal structure of TbPRMT7. Limited proteolysis on the full-length protein identified a stable, N-terminally truncated fragment spanning residues 32-390, referred to as TbPRMT7 in the remainder of the text for convenience. Notably, its catalytic activity is comparable with that of the full-length protein. To obtain phase information for the de novo structure determination, the protein was derivatized with seleno-methionine. The 2.8-Å crystal structure was solved using the single anomalous dispersion (SAD) phasing technique and refined to an R free /R work = 26.1/22.1%. For details of the data collection and refinement statistics, see Table S1 .
In an independent study, Wang et al. identified a similar core fragment of TbPRMT7 (residues 36-378) and determined its crystal structure in two different crystal forms (13) . Despite the alternative crystal packing, TbPRMT7 adopts the same compact, roughly rhombus-shaped homodimer, in which two protomers are arranged in an antiparallel fashion with a twofold symmetry axis perpendicular to the rhombus ( Fig. 2B) (13) . Because the dimeric TbPRMT7-S-adenosyl-L-homocysteine (AdoHcy) complexes are essentially identical in the different crystal forms with an rmsd of 0.5 Å for 670 Cα atoms, confirming the validity of the ; or (C) the H4 1-21 peptide with MMA substituted for arginine at position 3 (H4 1-21 R3MMA). Protein or peptides from the incubation were hydrolyzed and mixed with amino acid standards of ADMA, SDMA, and MMA and then analyzed via high-resolution cation-exchange chromatography. The red lines indicate the radioactivity of 3 H-methyl groups for complete reactions. The green lines indicate the radioactivity from a single control reaction where the enzyme alone was incubated with [methyl-3 H]-AdoMet as an automethylation control and is shown in each panel. The elution of the amino acid standards was determined by ninhydrin reactivity and is shown as a black dashed line. In each case, Lower represents an enlargement to show lower levels of methylation. Isotopically labeled ADMA, SDMA, and MMA elute about a minute earlier than the nonisotopically labeled standards due to the effect of tritium on the pK a s of the methylarginine species (11, 32) . The asterisked small radioactive peak in B, Lower migrates about 1 min earlier than expected for [ 3 H]ADMA-the identity of this material is unknown. dimeric structure, only key features of the overall structure are recapitulated below.
The structured core of a TbPRMT7 protomer resembles that of other PRMTs and consists of four modules: an N-terminal extension (residues 32-77), the AdoHcy-containing methyltransferase domain (residues 78-202), and the β-barrel domain (residues 203-390) that contains a protruding dimerization arm (residues 224-238) ( Fig. 2B) (13, 23, 24) . The two active sites that would bind the methyl donor AdoMet and the target arginine of the substrate are located ∼36 Å apart on the same face of the homodimer. The total buried surface area between the two protomers amounts to 7,560 Å 2 as calculated by the PISA server (26) and is primarily formed by the N-terminal extension and the dimerization arm and to a smaller degree by helices αE, αH′, and αK at the center of the dimer (Fig. 2B ).
Dimerization Is Necessary for TbPRMT7 Catalytic Activity. Using multiangle light scattering (MALS), we confirmed that TbPRMT7 exists as a dimer in solution ( Fig. S1 ), consistent with the large interface observed in the crystal structure and consistent with previous results from small-angle X-ray scattering (13) . To assess the importance of dimerization for catalysis, we created a mutant that is deficient in dimerization while keeping the active site intact. To this end, we replaced residues 224-235 of the dimerization arm with glycines. This dimerization arm mutant was exclusively monomeric in solution, indicating that the mutant is still properly folded whereas its catalytic activity was greatly reduced (Table 1 ). These data strongly suggest a requirement of dimerization for efficient catalysis. We confirmed this correlation with a second mutant, in which the N-terminal extension (residues 1-74 including helix αY) was truncated. Again, dimerization is abolished with a concomitant loss in catalytic activity (Table 1) . However, because helix αY of the N-terminal extension directly contributes several residues to the active site ( Fig. 3 ), the effect of helix αY removal cannot be solely ascribed to the dimerization deficiency.
Active Site of TbPRMT7. The active site of TbPRMT7 is formed by the methyltransferase domain, helix αY in the N-terminal extension, and a short motif of the β-barrel (Fig. 3 ). The cofactor product AdoHcy is well-defined in the electron density map, adopts its canonical conformation observed in AdoMet-dependent methyltransferases, and engages in highly conserved interactions with the methyltransferase domain (24) . AdoHcy sits in the lower part of the binding pocket with the methionine moiety at the bottom whereas the upper part of the cavity is poised for accommodating the incoming arginine of the substrate. The strongly negative electrostatic surface potential of the binding pocket is complementary to a substrate harboring a positively charged arginine residue (Fig. S2 ). Because the methyl group of AdoMet is transferred from its sulfur atom to a terminal nitrogen atom of the target arginine during catalysis, the residues adjacent to the sulfur atom of AdoHcy are expected to be most relevant for governing product specificity in TbPRMT7. The two conserved eponymous glutamate residues, Glu172 and Glu181, as well as Ile173 of the double E loop in the methyltransferase domain, form one side of the binding pocket (27) , opposed by Phe71 and His72 of helix αY in the N-terminal extension on the other side. The bottom of the pocket is formed by Met75 of helix αY whereas Gln329 and Trp330 of helix αK in the β-barrel domain are wedged between the methyltransferase domain and the N-terminal extension. The latter two residues are part of the THW motif termed after the threonine, histidine, and tryptophan residues predominantly found in type I PRMTs. In PRMT7 enzymes, however, methionine and glutamine substitute for the threonine and histidine residues. Comparison with the TbPRMT7-AdoHcy complex of another crystal form (PDB ID code 4M37) reveals that almost all activesite residues adopt identical positions and rotamers, with slight deviations observed for Met75, Glu172, Glu181, and Gln329.
Active-Site Mutations Decrease Type III Methylation Activity. To investigate the impact of individual residues on the methylation activity, mutations were made at key residues in the active site: e.g., the double E loop and THW motif (27) . Using TbRBP16 as a substrate, MMA production was assayed by amino acid analysis ( Table 1) . Several of the mutants displayed similar levels of MMA as WT TbPRMT7, including mutants for three residues in the double E loop (Ile173Val, Ile173Leu/Phe174Leu, and Gly180Tyr), a mutant of the THW motif (Gln329His), and two mutants in helix αY (Phe71Ala and Met75Phe). Although these mutations did not markedly affect activity, the remaining mutants displayed severe losses in activity, highlighting the significance of these residues in catalysis. Notably, no ADMA or SDMA product was formed in any of these mutants under conditions where 0.02% would have been detected.
A Mutation in the Double E Loop Converts TbPRMT7 into an ADMA-Producing Enzyme. The ability of PRMTs to dimethylate arginines to form either SDMA or ADMA relies on sufficient space within the active site to accommodate not only the unmodified but also the larger monomethylated arginine residue for subsequent dimethylation (28) . Notably, none of the mutants yielded any ADMA or SDMA with TbRBP16 or the H4 1-21 peptide. Many of these mutants showed significantly decreased activity, making it difficult to observe any level of possible dimethylarginine products. To overcome this limitation, the activity of certain mutants was tested with an already methylated H4 peptide at Arg3 (H4 1-21 R3MMA). When H4 1-21 R3MMA is used as a substrate with mutant Glu181Asp, we demonstrated production of both MMA and ADMA (Fig. 4C) . The MMA formed here presumably results from the methylation of the unmodified arginine-17 and/or arginine-19 residues. With the unmodified H4 1-21 peptide, the Glu181Asp mutant shows strictly type III activity ( Fig. 4 A and B) .
A similar mutational study of the first glutamate in TbPRMT7's double E loop (Glu172Asp) did not reveal any production of dimethylated arginine species. The side chain carboxyl atoms of the first glutamate residue in the TbPRMT7 double E loop (Glu172) have lower B-values than those of the second glutamate (Glu181), consistent with the deeper burial of Glu172 in the protein interior and its larger number of interactions with neighboring residues than the more solvent-exposed Glu181. A similar situation occurs for the first and second glutamate residues in the double E loop of other PRMTs (Table S2 ). To further confirm the production of ADMA, TLC was performed with acid hydrolysates of the methylation reaction and methylarginine standards. Radioactivity from TLC slices confirmed that the Glu181Asp mutant does produce both MMA and ADMA with the H4 1-21 R3MMA peptide (Fig. 4D ).
The TbPRMT7 Glu181Asp Mutant Has a Higher Affinity for the Monomethylated Peptide than WT TbPRMT7. To analyze peptide binding to the WT and mutant Glu181Asp enzymes, we performed isothermal titration calorimetry (ITC) with H4 1-21 and H4 1-21 R3MMA peptides (Fig. 5 ). Consistent with a strong electrostatic interaction, binding of the H4 1-21 peptide to TbPRMT7 was highly dependent on ionic strength, with relatively strong binding (K D = 2.7 μM) at low salt concentration (20 mM NaCl) and essentially no binding at 300 mM NaCl (K D = 0.4 M) (Table S3 ). The WT TbPRMT7 enzyme binds its substrate H4 1-21 with higher affinity (K D = 2.7 μM) than its monomethylation product H4 1-21 R3MM (K D = 9.1 μM), thermodynamically favoring product release. Although the affinity for the unmodified H4 1-21 peptide (K D = 2.0 μM) is essentially unchanged in the Glu181Asp mutant with respect to the WT enzyme, this mutant strikingly has increased binding affinity for the methylated peptide (K D = 1.5 vs. 9.1 μM of the WT). Thus, the Glu181Asp mutant favors binding of the bulkier H4 1-21 R3MM peptide, which can be rationalized by providing a more spacious binding pocket, stabilizing the MMA substrate-enzyme interactions and enabling dimethylation.
Discussion
We determined the crystal structure of a protein arginine methyltransferase, PRMT7 from T. brucei, in complex with the methyl donor product AdoHcy and performed biochemical and mutational analyses to elucidate its catalytic mechanism and the structural basis of its unique product specificity. Although various suggestions have been made for the role of specific residues in the active site of PRMTs and although a constricted active site has recently been suggested as the basis for MMA activity in different crystal forms of TbPRMT7 (13, 27), little is known experimentally about key residues that direct which methylarginine derivative is produced. This product specificity is crucial to the function of these enzymes because proteins that bind methylated substrates (so-called "methyl readers") differentially recognize ADMA and SDMA (3, 29) , and potentially MMA. Thus, defining the exact components of catalysis and product specificity for this class of enzymes has become increasingly important. Although it has not been established that the mammalian and trypanosomal PRMT7 enzymes have the same function, the degree of sequence identity (28% over the full-length TbPRMT7 protein compared with human PRMT7), its strict monomethylating behavior, and its robust enzymatic activity make the protozoan enzyme a facile system to study the biochemistry of type III PRMTs.
Notably, TbPRMT7 and mammalian PRMT7 have a distinct structural organization (9, 10, 13, 20) . Although the mammalian enzymes contain two PRMT cores in tandem, the trypanosomal enzyme contains only one PRMT core. However, our light scattering analysis (Fig. S1 ) as well as previous small-angle X-ray scattering studies (13) showed that TbPRMT7 forms a homodimer in solution. The juxtaposition of the two tandem PRMT cores in mouse and roundworm PRMT7 crystal structures recapitulates the dimeric TbPRMT7 architecture, sharing a similar overall quaternary structure (19, 20) . Although only one PRMT module is catalytically active in mouse PRMT7 (MmPRMT7) and roundworm PRMT7 (CePRMT7) (19, 20) , our data (Table 1) , as well as those of others, suggest that dimerization of PRMT7 cores-either by a noncovalent assembly or by juxtaposition of two units as part of one polypeptide-is a prerequisite for catalytic activity (19, 20) .
Another difference between mammalian and trypanosomal PRMT7 enzymes pertains to their substrate specificity (9, 10, 13, 20) . Human PRMT7, for example, has a substrate specificity for RXR motifs surrounded by basic residues, such as Arg17 and Arg19 in H4 1-21 (9, 10) , whereas our experiments with WT TbPRMT7 and the H4 1-21 peptide demonstrate that arginine methylation does not occur at this motif. By contrast, Arg3 is the major site of methylation in this peptide by TbPRMT7 (Fig. 1) , as indicated by the lack of MMA production above automethylation levels with the H4 1-21 peptide monomethylated at Arg3. Furthermore, the absence of any additional methylated species confirms the inability of TbPRMT7 to catalyze dimethylation reactions.
Site-directed mutagenesis experiments involving residues of the TbPRMT7 active site have given insight into key structural players of this enzyme's function. Several of the mutations are located in known PRMT motifs-including Gln329Ala in the THW motif as well as Glu172Gln and Glu181Gln in the double E loop (13, 27) . The importance of the double E loop in determining PRMT activity has been widely reported (27) because the methylated nitrogen atoms of the arginine(s) in substrate proteins are coordinated through these two glutamate residues (13, 24, 25) . These results demonstrate the importance of these residues on the activity of the TbPRMT7 enzyme.
By analyzing the effects that certain residues have on TbPRMT7 in a biochemical and structural context, we have identified Glu181 as a crucial molecular component of this enzyme's unique catalysis (Fig. 4) . In so doing, we have also expanded the current understanding of how type I and type III enzymes behave and why their methylation behavior differs from one another. A comparison of the distance between the two glutamate residues of the double E loop shows that the glutamates of the type III PRMTs are generally closer together (8.4 Å on average for TbPRMT7, PDB ID codes 4M36, 4M37, 4M38, and 5EKU; 6.8 Å for CePRMT7, PDB ID codes 3WST and 3XOD; and 8.7 Å for MmPRMT7, PDB ID code 4C4A) than those in type I PRMTs (e.g., 12.5 Å in RnPRMT1, PDB ID code 1ORI; 13.2 Å in MmPRMT6, PDB ID code 4C07; and 8.5 Å in HsPRMT4, PDB ID code 4IKP) ( Fig. S3) , consistent with the previous finding that TbPRMT7 features a smaller guanidine binding pocket with respect to type I and type II PRMTs (13) . The Glu181Asp mutation effectively shortens the side chain at that position by one carbon-carbon bond, increasing the distance between the flanking residues of the double E loop. An enlarged cavity would resemble the larger type I enzyme cavities more closely and allow for the recognition of an already methylated species, resulting in subsequent dimethylation. Indeed, our binding studies show a marked increase in affinity in the Glu181Asp mutant for a methylated substrate (H4 1-21 R3MMA) with respect to the WT enzyme (Fig. 5) . The Glu181Asp mutation still maintains the same charge at that position, allowing for similar interactions between the enzyme and the substrate's arginine, albeit at a weaker level. These findings provide a model for predicting the structural determinants of type I methylation, mediated by enzymes with longer distances between glutamates of the double E loop, versus type III methylation, mediated by enzymes with relatively shorter distances between the glutamates of the double E loop (about 1-2 Å shorter).
Product specificity plays also an important role in histone lysine methyltransferases (HKMTs) because mono-, di-, and trimethylation of lysines relay different biological signals and thus must be strictly controlled. A comparison between the structures of the lysine monomethyltransferase SET7/9 and the trimethyltransferase DIM-5 revealed that the different product specificity can be ascribed to a switch between a tyrosine in SET7/9 for a phenylalanine residue in DIM-5 (30, 31) . In detail, DIM-5 contains Phe281 in close proximity to the e-amino group of the target lysine. In SET7/9, Tyr305 occupies the equivalent position of Phe281 in DIM-5. The addition of the hydroxyl group in Tyr305 narrows the substrate channel and sterically hinders the insertion of a dimethylated e-amino group at the target lysine, resulting in strict monomethylation activity of SET7/9. Strikingly, the Phe281Tyr mutation in DIM-5 resulted in the alteration of product specificity from a trimethylated lysine to a mono-and dimethylated product whereas the reverse mutation of Tyr305Phe in SET7/9 abolished the strict monomethylation activity and allowed for the formation of di-and trimethylated product. This tyrosine/phenylalanine switch in HKMTs depicts the importance of the absence or presence of a single nonhydrogen atom in the active site for product specificity and recapitulates our finding of an analogous glutamate/aspartate switch that controls product specificity in PRMTs.
In conclusion, our biochemical and structural analyses have defined the components that restrict type III PRMTs to only monomethylate their target arginines and, more generally, have provided insights into the attributes that direct PRMT-mediated catalysis.
This knowledge not only will be useful for the prediction of the methylation behavior of novel, thus far uncharacterized members of this family but also will prove valuable in the rational (re)design of other PRMTs.
Methods
The details of molecular cloning, expression, purification, crystallization, X-ray diffraction data collection, structure determination, isothermal titration calorimetry, multiangle light scattering, and amino acid analysis of protein and peptide substrates are described in SI Methods. In short, TbPRMT7 was expressed in E. coli with an N-terminal His-tag. Recombinant proteins were purified using several chromatographic techniques. The structure was solved by SAD from seleno-L-methionine-labeled crystals.
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Debler et al. 10 .1073/pnas.1525783113 SI Methods Peptide Substrates. Histone H4 1-21 (Ac-SGRGKGGKGLGKGGA-KRHRKV) and histone H4 1-21 R3MMA (Ac-SGR[me]GKGGK-GLGKGGAKRHRKV) peptides were kind gifts from Heather Rust (The Scripps Research Institute, Jupiter, FL) and Paul Thompson (University of Massachusetts Medical School, Worcester, MA). The plasmid for expression of TbRBP16 (UniProt: Q9XY40) was a kind gift from Laurie Read (SUNY Buffalo, Buffalo, NY).
Protein Expression and Purification. DNA fragments of TbPRMT7 were amplified by PCR from genomic DNA, cloned into a pET28a vector (Novagen) containing an N-terminal PreScission protease (GE Healthcare) cleavable His 6 -tag, overexpressed in Escherichia coli BL21-CodonPlus(DE3)-RIL cells (Stratagene), and grown in LB media containing appropriate antibiotics. Mutations in TbPRMT7 were introduced by overlap extension PCR mutagenesis. Protein expression was induced at OD 600 ∼ 0.6 with 0.5 mM isopropyl-β-D-thiogalactoside at 18°C for 16 h. The cells were harvested by centrifugation at 7,500 × g and 4°C and lysed with a cell disrupter (Avestin) in a buffer containing 20 mM Tris, pH 8.0, 300 mM NaCl, 5 mM β-mercaptoethanol, 0.5 mM phenylmethylsulfonyl fluoride (Sigma), 2 μM bovine lung aprotinin (Sigma), and complete EDTA-free protease inhibitor mixture (Roche). After centrifugation at 35,000 × g for 45 min, the cleared lysate was loaded onto an Ni-NTA column (Qiagen) and eluted with an imidazole gradient. Protein-containing fractions were pooled, dialyzed against a buffer containing 20 mM Tris, pH 8.0, 100 mM NaCl, and 5 mM DTT, and subjected to cleavage with PreScission protease (GE Healthcare) for 12 h at 4°C. After His 6 -tag removal, the cleaved protein was bound to a heparin column (GE Healthcare) and eluted with an NaCl gradient. Proteincontaining fractions were pooled, concentrated, and purified on a HiLoad Superdex 200 16/60 gel filtration column (GE Healthcare) in a buffer containing 20 mM Hepes, pH 7.5, 150 mM NaCl, and 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP). His-tagged TbRBP16 was expressed and purified as previously described (33) , but the His-tag was removed.
Crystallization, Data Collection, Structure Determination, and Refinement.
For formation of the complex with the AdoHcy, 20 mg/mL of purified TbPRMT7 was mixed in a 1:2 molar ratio with AdoHcy and incubated for 1 h on ice. The crystallization solution consisted of 30% (wt/vol) PEG 400, 0.2 M MgCl 2 , and 0.1 M Tris, pH 8.0. Crystals grew in space group P3 2 21 at room temperature within 2 wk. X-ray diffraction data were collected at the X29 beamline at the National Synchrotron Light Source (NSLS) at the Brookhaven National Laboratory. Diffraction data were processed in HKL2000 (34) . The structure was solved by the single anomalous dispersion (SAD) phasing technique in the program AutoSol of the PHENIX package (35) , using data obtained from seleno-L-methionine-labeled crystals. The asymmetric unit contained one dimer. Model building was performed in O (36) and Coot (37) . The final model spanning residues 38-384 was refined in Phenix (35) to an R free of 26.1% with excellent stereochemistry as assessed by MolProbity (38) . Details for data collection and refinement statistics are summarized in Table S1 . Figures were generated using PyMOL (Schrödinger, LLC), and the electrostatic potential was calculated with APBS (39) . Atomic coordinates and structure factors have been deposited with the Protein Data Bank under PDB ID code 5EKU.
Multiangle Light Scattering. Purified proteins were characterized by multiangle light scattering after size-exclusion chromatography (40) .
Protein at 50 μM was injected onto a Superdex 200 10/300 GL sizeexclusion chromatography column (GE Healthcare) equilibrated in a buffer containing 20 mM Hepes, pH 7.5, 150 mM NaCl, and 0.5 mM TCEP. The chromatography system was connected in series with an 18-angle light scattering detector (DAWN HELEOS) and refractive index detector (OptilabrEX) (Wyatt Technology). Data were collected every second at a flow rate of 0.25 mL/min at 25°C. Data analysis was carried out using the program ASTRA, yielding the molar mass and mass distribution (polydispersity) of the sample.
Isothermal Titration Calorimetry. ITC measurements were performed at 15°C using a MicroCal auto-iTC200 calorimeter (MicroCal, LLC). Protein was incubated with twofold molar excess of AdoHcy for 1 h at room temperature. Protein and peptide samples were then extensively dialyzed against a buffer containing 20 mM Hepes, pH 7.5, 20 mM NaCl, and 0.5 mM TCEP. Then, 2 μL of 1-4 mM peptide was injected into 0.2 mL of 0.1-0.4 mM protein in the chamber every 150 s. Baselinecorrected data were analyzed with ORIGIN software.
Amino Acid Analysis of Protein and Peptide Substrates. Unless otherwise described, 5 μg of the TbRBP16 protein or 10 μM of the peptide substrates were methylated with 1.2 μg of WT TbPRMT7 or the indicated amount of mutant TbPRMT7 by incubating the mixture with 0.7 μM S-adenosyl-[methyl-3 H]-Lmethionine ([methyl-3 H]-AdoMet) [stock solution of 7 μM (78.2 Ci/mmol; PerkinElmer Life Sciences) in 10 mM H 2 SO 4 /EtOH (9:1, vol/vol)] in 50 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM DTT, and 5% (vol/vol) glycerol at 25°C for 16 h in a total volume of 60 μL. When TbRBP16 was used as the substrate, 60 μL of 25% (wt/vol) trichloroacetic acid and 20 μg of BSA were added to the reaction after completion, and the mixture was incubated at 25°C for 30 min, followed by centrifugation at 4,000 × g for 30 min at 25°C. The resulting pellet was washed with −20°C acetone before acid hydrolysis. Alternatively, when peptides were used as substrates, the reactions were quenched with 4 μL of 25% (wt/vol) trichloroacetic acid. For reactions that were used for TLC, the peptides were purified via RP-HPLC. For reactions that were used for cation exchange chromatography, peptides were purified using OMIX C18 Zip-Tips with elution in 15 μL of trifluoroacetic acid/acetonitrile/water (0.1:50:50). In both cases, elution solvent was removed by vacuum centrifugation. Acid hydrolysis of all samples was performed with 50 μL of 6 M HCl at 110°C for 20 h in vacuo. Once the acid was removed via vacuum centrifugation, the dried sample pellets were dissolved in 50 μL of water.
For samples analyzed by cation exchange chromatography, 1 μmol each of ω-MMA (acetate salt, M7033; Sigma), SDMA [di-(p-hydroxyazobenzene)-p-sulfonate salt, D0390; Sigma], and ADMA (hydrochloride salt; D4268; Sigma) were added as internal standards, and chromatography was then performed as previously described but using a buffer at pH 5.21 instead of 5.27 (10) . The positions of the nonradioactive methylarginine standards were determined by detecting the absorbance of 50-μL fraction aliquots at 570 nm after being reacted with ninhydrin, and radioactivity of the remaining 950 μL from each fraction was determined through liquid scintillation, using the average of three 5-to 20-min counting cycles, as described (10) . For samples analyzed by TLC, 10 μmol each of ω-MMA, SDMA, and ADMA were added to the peptide pellets. This mixture was dried via vacuum centrifugation and acid hydrolyzed as described above. Then, 10 μmol of the three standards were also acid hydrolyzed individually and as a group. The dried hydrolysates were resuspended in 10 μL of water. Each reaction hydrolysate and individual standard hydrolysate was spotted onto silica plates (Polygram Sil G/UV 254 , 805203; Macherey-Nagel) in 1-μL aliquots. Once the spots were dried, each plate was run in a 3:1 ethanol:water solvent mixture for about 8 h. After air drying, the plate was dipped momentarily in a ninhydrin solution [15 mg/mL ninhydrin dissolved in 97% (vol/vol) butanol, 3% (vol/vol) glacial acetic acid]. The plate was again allowed to air dry and then heated at 90°C for 15 s. Visible ninhydrin spots were outlined, and the plate was sectioned into 5-mm-wide slices. The silica from each slice was mixed with 500 μL of water and vortexed for 2 h. This material was added to 5 mL of scintillation fluid to detect radioactivity using the average of three 20-min cycles. The dissociation constant (K D ), binding enthalpy (ΔH), and the stoichiometry (N) were derived by curve fitting using a single-site model whereas the entropy (ΔS) was calculated from these values. n/a, not applicable.
